More recently, the development of a cetuximab-conjugated gold nanoparticle in the colorectal cancer cell, showed greater cytotoxicity versus standard cetuximab, probably because of tumor phenotype modulation by nanomaterials which contributed to upregulation of the anti-EGFR pathway (i.e., EpCAM, CMAM, and HER-3) [71]. This evidence concerns the gene EGFR and neoplasm.